Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer ’s disease

ConclusionsThese results highlight the new concept that combined A β and tau thresholds can predict imminent neurodegeneration as an alternative framework with a high statistical power for testing the effect of disease-modifying therapies on [18F]FDG uptake decline over a typical 2-year clinical trial period in individuals with preclinical AD.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research